Chemosensitivity/Resistance Assay Included As Part of the NCCN Principles of Chemotherapy

Patients, Physicians Rely on ChemoFx^® to Support Their Cancer Treatment Decisions

Precision Therapeutics CEO Presents at J.P. Morgan 28th Annual Healthcare Conference

Precision Therapeutics to Present at Jeffries 2010 Global Healthcare Services Conference

Precision's Quarterly Newsletter

Precision Therapeutics heading to Pittsburgh's Lawrenceville neighborhood

Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetter Award

Pittsburgh-based tech firm clarifies approval process

Precision Therapeutics named to INC. Magazine's list of fastest growing companies

Precision's Quarterly Newsletter

May 18, 2009

OCNA sends an open letter to the Payer community

May 2009

ChemoFx® offers hope to cancer patients

March 2009

Precision's Quarterly Newsletter

November 10, 2008

Precision secures $43 million in funding

September 5, 2008

Watch! Individualized Treatment for Cancer Catching On

July 10, 2008

Precision publishes new article in Cancer Cell International

July 2008

Precision's Quarterly Newsletter

July 1, 2008

Precision Announces Study Results: ChemoFx^® Correlates with Outcomes in Breast Cancer

June 30, 2008

Sean McDonald named Entrepreneur of the Year Winner

May 20, 2008

Precision Announces Study Results at ASCO: ChemoFx^® Correlates with Survival in Ovarian Cancer

April 2008

Precision's Quarterly Newsletter

April 8, 2008

Precision Adds 8 Million Covered Lives Under Contract

February 22, 2008

Oracle Healthcare and Precision Merger Plan Amended

December 4, 2007

Oracle Healthcare and Precision Therapeutics announce Merger

October 2007

Precision Announces Study Results with Independent Cytopathologist

August 2, 2007

Genetic Tests for Treatment Growing Part of Health Care Field

July 11, 2007

Making Medicine Personal

May 7, 2007

Precision Therapeutics Hires Matt Marshall as Vice President

February 22, 2006

Precision Therapeutics Gets $20M Series B for Growth

February 22, 2006

Precision's Series B Adds $20M for Cancer Regimen

February 18, 2006

Company gets $20M in Venture Capital

February 15, 2006

Finding The Best Treatment for Recurrent Ovarian Cancer

January 31, 2006

ChemoFx^® Improves Therapy Effectiveness for Ovarian Cancer Patients